This is a thought provoking post from yesterday's PharmaTech Talk blog written by Patricia Van Arnum. It questions whether simultaneous Big Pharma investments in emerging markets (mostly with generics) and established product growth strategies will yield the growth results these companies are seeking?
It would appear that many in the Big Pharma world are pursuing this same strategy and in some cases they are pitting growth of their generics in emerging markets (where generics are already entrenched across the competition) with their established products also trying to grow in emerging geographic markets? Is there anough "free share" in the market to go around especially with reduced margins seen with generics?
Well, that's what the next 5 years will tell us.
Posted by Bruce Lehr May 12th 2010.